Nasus Pharma Ltd
NSRXNYSE
$3.01
↓ -2.0%Jul 17 close · end-of-day
Price
1Y↓ -63.5%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$24.1M
Enterprise Value
$22.9M
P/E
—
P/S
0.0
P/B
8.7
EV/EBITDA
—
PEG
—
FCF Yield
-20.5%
Dividend Yield
—
Revenue (TTM)
$1.2B
Net Income (TTM)
-$5.9M
Free Cash Flow (TTM)
-$4.9M
Gross Margin
—
Operating Margin
-0.4%
Net Margin
-0.5%
ROE
-211.6%
ROIC
-253.1%
Debt / Equity
—
Net Cash
$1.2M
Return 1Y
—
Company profile
We are a clinical-stage specialty pharmaceutical company focused primarily on the development of intranasal drugs to treat emergency medical conditions. Intranasal administration is especially suitable for medical emergencies when prompt drug administration is critical, since the nose is lined up with a very rich vascular bed enabling quick drug absorption. Our principal executive offices are located in Tel Aviv, Israel.
- CEO
- Dan Teleman
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 2
- Website
- www.nasuspharma.com/
Management & directors
- Teleman Dan BenjaminChief Executive Officer
Roles derived from SEC Form 4 filings.
Earnings
No reported earnings periods on file.
Financial statements
| Line item | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Revenue | — | — | $1.2B |
| Gross profit | — | — | — |
| Operating income | -$1.1M | -$1.1M | -$4.9M |
| Net income | -$1.1M | -$1.5M | -$5.9M |
| Diluted EPS | -$0.20 | -$0.22 | -$0.72 |
| Operating cash flow | -$1.0M | -$665,000.00 | -$4.9M |
| Free cash flow | — | — | -$4.9M |
| Gross margin | — | — | — |
| Operating margin | — | — | -0.4% |
| Net margin | — | — | -0.5% |
No quarterly data.
Company news
Jun 23, 2026
Jun 22, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-17 | Teleman Dan Benjamin· Chief Executive Officer | Buy | 6,550 | $3.10 | $20,305.00 | filing |
| 2026-04-22 | Teleman Dan Benjamin· Chief Executive Officer | Buy | 2,900 | $3.76 | $10,904.00 | filing |
| 2026-03-31 | Teleman Dan Benjamin· Chief Executive Officer | Buy | 15,000 | $2.04 | $30,600.00 | filing |
Latest 3 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.